Guangzhou Baiyunshan Pharmaceutical Holdings
Market Cap
HK$50.2b
Last Updated
2020/05/30 12:42 UTC
Data Sources
Company Financials +
Executive Summary
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited researches, develops, manufactures, and sells Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and chemical raw material intermediates in the People’s Republic of China and internationally.
Rewards
Risk Analysis
Snowflake Analysis
Excellent balance sheet and fair value.
Similar Companies
Share Price & News
How has Guangzhou Baiyunshan Pharmaceutical Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 874's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
0.5%
874
-0.4%
HK Pharmaceuticals
0.6%
HK Market
1 Year Return
-42.5%
874
-2.5%
HK Pharmaceuticals
-9.9%
HK Market
Return vs Industry: 874 underperformed the Hong Kong Pharmaceuticals industry which returned -4.2% over the past year.
Return vs Market: 874 underperformed the Hong Kong Market which returned -10.4% over the past year.
Shareholder returns
| 874 | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.5% | -0.4% | 0.6% |
| 30 Day | -8.1% | 2.0% | -3.6% |
| 90 Day | -20.8% | -0.8% | -6.8% |
| 1 Year | -41.7%-42.5% | -1.0%-2.5% | -7.0%-9.9% |
| 3 Year | -9.2%-13.0% | 9.5%4.8% | -4.7%-14.3% |
| 5 Year | -34.6%-39.4% | 19.4%10.7% | -15.4%-28.5% |
Price Volatility Vs. Market
How volatile is Guangzhou Baiyunshan Pharmaceutical Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
Valuation
Is Guangzhou Baiyunshan Pharmaceutical Holdings undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 874 (HK$18.84) is trading below our estimate of fair value (HK$61.51)
Significantly Below Fair Value: 874 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 874 is good value based on its PE Ratio (9.5x) compared to the Pharmaceuticals industry average (10x).
PE vs Market: 874 is poor value based on its PE Ratio (9.5x) compared to the Hong Kong market (9.3x).
Price to Earnings Growth Ratio
PEG Ratio: 874 is poor value based on its PEG Ratio (1.6x)
Price to Book Ratio
PB vs Industry: 874 is overvalued based on its PB Ratio (1.1x) compared to the HK Pharmaceuticals industry average (1.1x).
Next Steps
Future Growth
How is Guangzhou Baiyunshan Pharmaceutical Holdings forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
5.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 874's forecast earnings growth (6.1% per year) is above the savings rate (1.6%).
Earnings vs Market: 874's earnings (6.1% per year) are forecast to grow slower than the Hong Kong market (16.5% per year).
High Growth Earnings: 874's earnings are forecast to grow, but not significantly.
Revenue vs Market: 874's revenue (6.7% per year) is forecast to grow slower than the Hong Kong market (10.5% per year).
High Growth Revenue: 874's revenue (6.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 874's Return on Equity is forecast to be low in 3 years time (12.9%).
Next Steps
Past Performance
How has Guangzhou Baiyunshan Pharmaceutical Holdings performed over the past 5 years?
24.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 874 has high quality earnings.
Growing Profit Margin: 874's current net profit margins (4.6%) are lower than last year (7.4%).
Past Earnings Growth Analysis
Earnings Trend: 874's earnings have grown significantly by 24.5% per year over the past 5 years.
Accelerating Growth: 874's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 874 had negative earnings growth (-24.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (2.7%).
Return on Equity
High ROE: 874's Return on Equity (11.9%) is considered low.
Next Steps
Financial Health
How is Guangzhou Baiyunshan Pharmaceutical Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: 874's short term assets (CN¥45.6B) exceed its short term liabilities (CN¥27.8B).
Long Term Liabilities: 874's short term assets (CN¥45.6B) exceed its long term liabilities (CN¥1.5B).
Debt to Equity History and Analysis
Debt Level: 874's debt to equity ratio (32.9%) is considered satisfactory.
Reducing Debt: 874's debt to equity ratio has increased from 7.3% to 32.9% over the past 5 years.
Debt Coverage: 874's debt is well covered by operating cash flow (49.2%).
Interest Coverage: 874 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Next Steps
Dividend
What is Guangzhou Baiyunshan Pharmaceutical Holdings's current dividend yield, its reliability and sustainability?
3.40%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 874's dividend (3.39%) is higher than the bottom 25% of dividend payers in the Hong Kong market (2.65%).
High Dividend: 874's dividend (3.39%) is low compared to the top 25% of dividend payers in the Hong Kong market (7.31%).
Stability and Growth of Payments
Stable Dividend: 874's dividend payments have been volatile in the past 10 years.
Growing Dividend: 874's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (32.3%), 874's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.8yrs
Average management tenure
CEO
Hong Li (52yo)
2.92yrs
Tenure
CN¥1,344,894
Compensation
Mr. Hong Li has been General Manager at Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited since June 23, 2017 and serves as its Executive Director since June 22, 2018. Mr. Li started his career ...
CEO Compensation Analysis
Compensation vs Market: Hong's total compensation ($USD188.22K) is below average for companies of similar size in the Hong Kong market ($USD602.26K).
Compensation vs Earnings: Hong's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 6.75yrs | no data | 0.0031% CN¥1.5m | |
| GM & Executive Director | 2.92yrs | CN¥1.34m | 0.00031% CN¥155.5k | |
| Vice Chairman | 0.92yr | no data | 0.00066% CN¥331.1k | |
| Deputy GM & Executive Director | 9.92yrs | CN¥1.31m | 0.00040% CN¥200.7k | |
| Executive Director | 6.33yrs | no data | 0.00040% CN¥200.7k | |
| Deputy GM & Executive Director | 0.92yr | CN¥784.30k | 0.00031% CN¥155.5k | |
| Deputy General Manager | 0.83yr | CN¥805.98k | no data | |
| Deputy GM & Director of Business Administration Department | 0.83yr | CN¥547.87k | no data | |
| Secretary | 1.75yrs | CN¥990.90k | no data | |
| Executive Director | 0.33yr | no data | no data |
1.8yrs
Average Tenure
50.5yo
Average Age
Experienced Management: 874's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 6.75yrs | no data | 0.0031% CN¥1.5m | |
| GM & Executive Director | 2.92yrs | CN¥1.34m | 0.00031% CN¥155.5k | |
| Vice Chairman | 0.92yr | no data | 0.00066% CN¥331.1k | |
| Deputy GM & Executive Director | 9.92yrs | CN¥1.31m | 0.00040% CN¥200.7k | |
| Executive Director | 6.33yrs | no data | 0.00040% CN¥200.7k | |
| Deputy GM & Executive Director | 0.92yr | CN¥784.30k | 0.00031% CN¥155.5k | |
| Executive Director | 0.33yr | no data | no data | |
| Independent Non-Executive Director | 16.17yrs | CN¥100.00k | no data | |
| Independent Non-Executive Director | 6.33yrs | CN¥100.00k | no data | |
| Chairman of the Supervisory Board | 0.33yr | no data | 0.00046% CN¥230.8k |
4.1yrs
Average Tenure
53yo
Average Age
Experienced Board: 874's board of directors are considered experienced (4.1 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
- Ticker: 874
- Exchange: SEHK
- Founded: 1997
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$50.171b
- Shares outstanding: 1.63b
- Website: https://www.gybys.com.cn
Number of Employees
Location
- Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
- 45 Sha Mian North Street
- Liwan District
- Guangzhou
- Guangdong Province
- 510130
- China
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| GZPH.F | OTCPK (Pink Sheets LLC) | Yes | Foreign Shares-Foreign Listed | US | USD | Oct 1997 |
| 874 | SEHK (The Stock Exchange of Hong Kong Ltd.) | Yes | Foreign Shares-Foreign Listed | HK | HKD | Oct 1997 |
| GU5 | DB (Deutsche Boerse AG) | Yes | Foreign Shares-Foreign Listed | DE | EUR | Oct 1997 |
| 874 | SHSC (Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect) | Yes | Foreign Shares-Foreign Listed | HK | HKD | Oct 1997 |
| 874 | SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect) | Yes | Foreign Shares-Foreign Listed | HK | HKD | Oct 1997 |
| 600332 | SHSE (Shanghai Stock Exchange) | Domestic Shares | CN | CNY | Feb 2001 | |
| 600332 | XSSC (Shanghai Stock Exchange - Shanghai - Hong Kong Stock Connect) | Domestic Shares | CN | CNY | Feb 2001 |
Biography
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited researches, develops, manufactures, and sells Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and chemical raw material intermediates in the People’s Republic of China and internationally. It operates through four segments: Great Southern TCM, Great Commerce, Great Health, and Others. The company is also involved in the wholesale, retail, import, and export of Western medicines, Chinese medicines, and medical apparatus, instruments, and equipment; investment in health industry with medical care, health management, health maintenance, elderly care, etc.; and research and development, production, and sale of beverage, food, healthcare products, pre-packaging food, dairy products, etc., as well as tea, ganoderma spore oil capsules, lozenges, tortoise herb jelly, etc. It also provides commercial services; and advertising services. As of December 31, 2019, it had 108 retail chain pharmacy outlets, which included 33 Cai Zhi Lin pharmacy outlets, 35 Jian Min pharmacy outlets, 21 GPC Prescription Pharmacy outlets, 17 Hainan Guangyao Chenfei Pharmaceutical outlets, and 2 Hainan Guangyao Chenfei Pharmaceutical Chain outlets. The company was formerly known as Guangzhou Pharmaceutical Company Limited and changed its name to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited in August 2013. Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited was founded in 1997 and is based in Guangzhou, China.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/05/30 12:42 |
| End of Day Share Price | 2020/05/29 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.